Several other brokerages also recently weighed in on MYGN. Ladenburg Thalmann Financial Services upgraded Myriad Genetics from a sell rating to a neutral rating in a research note on Wednesday. TheStreet downgraded Myriad Genetics from a hold rating to a sell rating in a research note on Tuesday, November 1st. Zacks Investment Research upgraded Myriad Genetics from a sell rating to a hold rating in a research note on Wednesday, February 1st. Piper Jaffray Companies reiterated a neutral rating and set a $21.00 price target on shares of Myriad Genetics in a research note on Tuesday. Finally, Barclays PLC reiterated an equal weight rating and set a $22.00 price target on shares of Myriad Genetics in a research note on Tuesday, December 27th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $27.64.
Jefferies Group LLC reissued their hold rating on shares of Myriad Genetics, Inc. (NASDAQ:MYGN) in a report issued on Wednesday morning. The brokerage currently has a $18.00 target price on the stock.
Shares of Myriad Genetics (NASDAQ:MYGN) traded down 2.30% on Wednesday, hitting $16.14. The stock had a trading volume of 1,990,762 shares. Myriad Genetics has a 12 month low of $15.15 and a 12 month high of $39.74. The company’s 50 day moving average price is $16.45 and its 200-day moving average price is $19.67. The company has a market cap of $1.10 billion, a P/E ratio of 18.24 and a beta of 0.26.
Myriad Genetics (NASDAQ:MYGN) last announced its earnings results on Tuesday, February 7th. The company reported $0.26 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.02. Myriad Genetics had a return on equity of 11.94% and a net margin of 8.08%. The firm had revenue of $196.50 million for the quarter, compared to the consensus estimate of $189.72 million. During the same period in the previous year, the business earned $0.45 EPS. The firm’s revenue for the quarter was up 1.7% on a year-over-year basis. On average, analysts expect that Myriad Genetics will post $0.98 earnings per share for the current year.
A number of institutional investors have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC boosted its position in Myriad Genetics by 96.2% in the third quarter. Acrospire Investment Management LLC now owns 10,400 shares of the company’s stock worth $214,000 after buying an additional 5,100 shares during the last quarter. Zacks Investment Management purchased a new position in shares of Myriad Genetics during the third quarter worth approximately $273,000. Lombardia Capital Partners LLC purchased a new position in shares of Myriad Genetics during the third quarter worth approximately $319,000. Royal Bank of Canada boosted its position in shares of Myriad Genetics by 21.6% in the second quarter. Royal Bank of Canada now owns 10,431 shares of the company’s stock worth $321,000 after buying an additional 1,851 shares during the last quarter. Finally, Commerzbank Aktiengesellschaft FI boosted its position in shares of Myriad Genetics by 1.4% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 21,376 shares of the company’s stock worth $356,000 after buying an additional 301 shares during the last quarter.
Myriad Genetics Company Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.